Tocilizumab in patients with severe COVID-19: a retrospective cohort study - The Lancet Rheumatology
How is Actemra® (tocilizumab) for GCA believed to work?
Frontiers | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
Single Technology Appraisal Tocilizumab for treating giant cell arteritis Committee Papers
Frontiers | Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review
Actemra Side Effects: Common, Severe, Long Term - Drugs.com
COVID-19 Clinical Trials Safety Side Effects | ACTEMRA® (tocilizumab)
PDF) Long-term treatment with tocilizumab in giant cell arteritis: Efficacy and safety in a monocentric cohort of patients
Tocilizumab for relapsing and remitting giant cell arteritis: a case series | Journal of Medical Case Reports | Full Text
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial - The Lancet Rheumatology
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
TOCILIZUMAB
Actemra Side Effects: Common, Severe, Long Term - Drugs.com
Effects of long-term infliximab and tocilizumab treatment on anxiety-like behavior and cognitive function in naive rats | SpringerLink
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
Healthcare | Free Full-Text | Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
PDF) Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial - The Lancet Rheumatology
Frontiers | Tocilizumab and COVID-19: Timing of Administration and Efficacy
Tocilizumab for relapsing and remitting giant cell arteritis: a case series | Journal of Medical Case Reports | Full Text
Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid Arthritis
GCA Clinical Trial Results | ACTEMRA® (tocilizumab)
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial - The Lancet Rheumatology
